Ramy Farid, Ph.D.

Director

Ramy Farid, Ph.D., has served as a member of our Board since May 2024.

Dr. Farid is President, Chief Executive Officer, and a member of the Board of Directors at Schrödinger, Inc., which has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. He joined Schrödinger in 2002 and helped advance the company’s computational platform and drug discovery portfolio while assuming positions of increasing responsibility before becoming Chief Executive Officer in 2017. 

Dr. Farid has played a key role in implementing major strategic initiatives at Schrödinger, including more than 40 research collaborations and joint ventures, and led the company through its initial public offering in 2020. Dr. Farid currently serves on the board of directors of Ajax Therapeutics, Inc., a private biotechnology company (and collaboration partner of Schrödinger). Previously, he served on the boards of directors of Structure Therapeutics Inc., a U.S. publicly traded biopharmaceutical company, Morphic Therapeutic, Inc., a U.S. publicly traded biopharmaceutical company (later acquired by Eli Lilly and Company in August 2024), Nimbus Therapeutics, a private biotechnology company (which he helped found in 2009), and Oak Hill Bio Ltd. a private biotechnology company. 

Dr. Farid began his career in academia and was an assistant professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his doctorate degree in chemistry from Caltech. He is an author on over 100 peer reviewed publications.